JPRN-UMIN000043313
Recruiting
未知
Imaging evaluation of estrogen receptor in breast cancer - Imaging evaluation of estrogen receptor in breast cancer
ConditionsBreast cancer
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- Breast cancer
- Sponsor
- Kyoto University
- Enrollment
- 300
- Status
- Recruiting
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- •1\. Patients who received selective estrogen receptor modulators (SERMs) or selective estrogen down regulators (SERDs) within 5 weeks prior to \[18F] FES\-PET 2\. Patient who had adverse reactions to \[18F]FES in the past 3\. Women who are or may be pregnant 4\. Patients in extremely poor general condition 5\. Patients with significant communication difficulties 6\. Patients judged not to be appropriate for attending this study by investigators
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Phase 1
Estrogen receptor and androgen receptor imaging in metastatic breast cancer patientsEUCTR2012-003981-42-NLniversity Medical Center Groningen
Completed
Early Phase 1
Fluorestradiol (FES) PET/CT for Imaging Estrogen Receptor StatusBreast CancerNCT01916122Memorial Sloan Kettering Cancer Center54
Completed
Phase 2
Androgen receptor and estrogen receptor imaging in metastatic breast cancer patientsbreast cancer10006291NL-OMON39731niversitair Medisch Centrum Groningen20
Completed
Phase 2
AR and ER Imaging in Metastatic Breast CancerMetastatic Breast CancerNCT01988324University Medical Center Groningen24
Completed
Phase 2
Palbociclib and FES PETBreast CancerNCT02806050University Medical Center Groningen30